Compare Medtronic PLC (MDT) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Oklo Inc — how do they compare? Medtronic PLC trades at $88.48 (market cap $112.24B), while Oklo Inc trades at $34.7 (market cap $6.43B). The key difference: Medtronic PLC is far larger — about 17.5× Oklo Inc's market cap, and Medtronic PLC pays a 3.28% dividend while Oklo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Oklo Inc for 32 Days on average.
| MDT | OKLO | |
|---|---|---|
Market Cap | $112.24B | $6.43B |
Volume | 105,663,236 | 16,238,368 |
Sector | Health | Utilities |
52-Week High | $105.35 | $174.14 |
52-Week Low | $73.75 | $34.57 |
Typical Hold Time | 63 Days | 32 Days |
Enterprise Value | $131.58B | $3.97B |
Dividend Yield | 3.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $87.75, up 2.62% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 49-year dividend growth streak. The stock shows bearish technical signals but maintains solid profitability with 13.93% net margins and positive cash flow trends. Recent regulatory approvals for medical devices and raised guidance signal operational momentum despite mixed technical indicators.
Outlook remains positive with analyst consensus at $97.80 (11% upside) and no sell ratings, though technical weakness and increasing debt-to-asset ratios pose near-term risks. The 3.2% dividend yield provides income support while revenue growth acceleration to $37.5B projected for 2026 offers growth potential.
OKLO trades at $34.57, down 6.11% with bearish technical signals despite strong analyst support. The company shows no revenue in 2025 with significant losses (-$105.66M net income) and negative margins, though cash flow from financing provides runway. Recent news highlights nuclear sector volatility and OKLO's $1 billion stock sale raising dilution concerns.
Outlook hinges on project execution amid high risk-reward dynamics. Analyst consensus is bullish (71% Buy) with a $78.63 price target, but profitability challenges and cash burn pose substantial risks. Success depends on commercializing its nuclear reactor pipeline to capitalize on the growing AI power demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
